Glioma of Brain Clinical Trial
Official title:
A New Strategy for the Visulation of Molecular Genotype in Glioma Evolution Based on the Radiomics and Microomics
The key molecular changes in the progression of glioma are closely related to tumor heterogeneity, pathological grade, precision treatment and prognosis of glioma. At present, a visually quantitative assessment criteria about the key molecular typing of glioma is still absent. Based on the previous research, this project intends to establish a multi-dimensional database of glioma from clinical, radiomics and microomics levels. The investigators aim to filter out the specific molecular markers in the progression of glioma and explore the intrinsic connection of radiomics features and microomics molecular markers by using bioinformatics integration analysis and artificial intelligence multiple kernel learning. Thus, the investigators could determine the specific molecular mechanism in the progression of glioma, and establish a visually quantitative assessment system of pre-operative precisive grading, molecular typing discrimination and prognosis prediction. The completion of this project is of great significance for improving molecular diagnostic level of glioma, guiding individualized diagnosis and treatment decisions, and improving the survival rate of patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03796507 -
Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
|
Early Phase 1 | |
| Withdrawn |
NCT04406610 -
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03189420 -
Glioma Microenvironment an Exploratory Study
|
||
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03739372 -
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
|
N/A | |
| Completed |
NCT03779230 -
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03728673 -
A Study Utilizing Escitalopram in Glioma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03496181 -
Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
|
||
| Recruiting |
NCT03180697 -
The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
|
N/A | |
| Recruiting |
NCT03949192 -
Efficacy of Kangliuwan for Recurrent Grade IV Glioma
|
||
| Terminated |
NCT03927274 -
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
|
Early Phase 1 | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Terminated |
NCT03698201 -
Blood Biomarker Signature in Glioma
|
||
| Terminated |
NCT03436433 -
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
|
Phase 2 | |
| Enrolling by invitation |
NCT03102112 -
Noninvasively Predicting Gene Status of Glioma
|
N/A | |
| Active, not recruiting |
NCT03935685 -
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
|
Phase 2 | |
| Completed |
NCT03834740 -
A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
|
Early Phase 1 | |
| Recruiting |
NCT03849430 -
Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients
|